Phase 1b clinical trials

Explore recruiting phase 1b clinical trials.

Recruiting phase 1b studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Phase 1b trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A First-in-human, Phase 1/2, Multicenter, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor activity of ADCE-D01, a Humanized Anti-human uPARAP Antibody Linked to a Topoisomerase I Inhibitor, in Patients with Metastatic and/or Unresectable Soft Tissue Sarcoma

Belgium, Germany, France

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Phase 1b/2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301)

France, Hungary, Romania, Spain, Netherlands, Finland +9 more

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A FIRST-IN-HUMAN (FIH) STUDY OF IDRX-42 IN PARTICIPANTS WITH METASTATIC AND/OR UNRESECTABLE GASTROINTESTINAL STROMAL TUMORS (GIST)

France, Spain, Netherlands, Germany, Belgium, Italy

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Open label, non-randomized, Phase 1b/2 trial investigating the safety, tolerability, and antitumor activity of S095029 (anti-NKG2A antibody) as a part of combination therapy in participants with locally advanced and unresectable or metastatic MSI-H/dMMR gastro-esophageal junction/gastric cancer

Spain, Italy, Belgium, France, Austria, Denmark +1 more

Phase I and Phase II (Integrated)- Other EU CTIS Study details

An open-label, multicenter, Phase 1b/2a study to evaluate efficacy, safety, tolerability, and pharmacokinetics of the ATR inhibitor Tuvusertib (M1774) in combination with cemiplimab in participants with non-squamous non-small cell lung cancer that has progressed on prior anti-PD-(L)1 and platinum-based therapies (DDRiver NSCLC 322)

Spain, Italy, Belgium, Germany, France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A multicentre, open-label, non-randomized, phase 1a/1b study of NG 641, a tumour-selective and transgene-expressing adenoviral vector, in combination with nivolumab (or standard of care PD-1 inhibition) in patients with metastatic or advanced epithelial tumours (NEBULA)

Belgium, Spain

Human Pharmacology (Phase I)- Other EU CTIS Study details

Phase 1b trials by city

Phase 1b in Toronto Phase 1b in Vancouver Phase 1b in Montreal Phase 1b in Calgary Phase 1b in Edmonton Phase 1b in Ottawa Phase 1b in Winnipeg Phase 1b in Quebec City Phase 1b in Hamilton Phase 1b in Kitchener Phase 1b in London Phase 1b in Halifax Phase 1b in New York Phase 1b in Los Angeles Phase 1b in Chicago Phase 1b in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease